The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, characterized by its aggressive tumor biology and poor prognosis. While immune checkpoint inhibitors (ICIs) play a major part in the treatment algorithm of various solid tumors, there is still no evidence of clinical benefit from ICI in patients with metastatic PDAC (mPDAC). This might be due to several reasons, such as the inherent low immunogenicity of pancreatic cancer, the dense stroma-rich tumor microenvironment that precludes an efficient migration of antitumoral effector T cells to the cancer cells, and the increased proportion of immunosuppressive immune cells, such as regulatory T cells (Tregs), cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs), facilitating tumor growth and invasion. In this review, we provide an overview of the current state of ICIs in mPDAC, report on the biological rationale to implement ICIs into the treatment strategy of pancreatic cancer, and discuss preclinical studies and clinical trials in this field. Additionally, we shed light on the challenges of implementing ICIs into the treatment strategy of PDAC and discuss potential future directions.

Automated summary

This review provides an overview of the current state of immune checkpoint inhibitors (ICIs) in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). It discusses the biological rationale for implementing ICIs and explores preclinical studies and clinical trials in this field. The challenges of integrating ICIs into the treatment strategy of PDAC and potential future directions are also addressed.